Production and Purification of Recombinant Proteins from Escherichia coli

Abstract

Development of successful production strategies for recombinant proteins is a challenging task due to problems associated with the scale‐up of bioprocesses. Recent developments in fermentation technology have provided a suitable platform to produce bioproducts for the development of diagnostics, therapeutics and vaccines for bacterial, viral and other diseases. A bacterial system is the commonly used expression system for production of recombinant products such as proteins, enzymes, and antibodies. Escherichia coli is one of the most commonly used bacterial hosts for the production of these products. A variety of recombinant proteins has been produced and cultivation studies have been carried out at small scale. However, the majority of the recombinant proteins are not amenable directly to large scale production processes due to various factors. To meet the growing demand of potential bioproducts, there is a need to produce these products in large quantity employing fermentation processes. Development of a suitable purification strategy is yet another important step to recover biologically active products. The present paper reviews the current developments in production and purification of recombinant products from E. coli. The bioproducts obtained after fermentation and purification processes may fulfill the requirements for the development of various diagnostics, therapeutics, or prophylactic agents against different kinds of diseases.

Advancement of sensor technology for monitoring and control of upstream bioprocesses

“…The reasons may be connected to the price of the products and the market situation. Still, application of the singleuse reactors has important advantages including the eliminated risk of batch-to-batch product contamination and the decreased production costs through reducing the workload of cleaning, sterilization and validation [29]. The main motivation for using disposable bioreactors for culturing 2.3.…”

In Vivo Removal of N-Terminal Fusion Domains From Recombinant Target Proteins Produced in Nicotiana benthamiana

“…Although the bacterial system was the first to be developed, animal cell cultures are now the most widely used systems for producing the recombinant proteins used in protein drugs. The advantages and disadvantages of the different systems depend on the type of recombinant protein under production (Tripathi, 2016;Bielser et al, 2018;Hitzeman et al, 2018;Owczarek et al, 2019;Schillberg et al, 2019).…”

Zymobacter palmae pyruvate decarboxylase production process development: Cloning in Escherichia coli, fed‐batch culture and purification

“…Approximately 90% of all industrial enzymes are produced by recombinant microorganisms, especially for high‐volume, low‐value enzymes . The use of E. coli as a host for recombinant protein production is the most common strategy for process development . Thus, gram negative bacteria remain the preferred system for laboratory investigations and initial development in commercial activities and is a benchmark for comparison with other expression platforms .…”